Elim Biopharm
RightOn
Cancer Panel
RightOn Cancer Sequencing Kits provide a convenient, accurate and cost-effective target enrichment solution for next generation cancer sequencing. The superior library prep and target enrichment technologies enable researchers to accurately and cost-effectively identify common and rare genetic variants in over 1,000 cancer genes with one single test.
RightOn Cancer Sequencing
Key Benefits
Comprehensive and Convenient
RightOn Cancer Sequencing targets 3.6 Mb of > 1,000 cancer genes. A large cancer panel enables comprehensive profiling of all cancer types with one single test.
Exceptional Coverage & Specificity
Achieve 100x minimum coverage on >98% of targeted bases with relatively low sequencing data. Achieve high specificity with precise coverage on targeted bases only. This deep coverage and exceptional specificity allow accurate profiling of common and rare cancer variants.
High
Sensitivity
RightOn Cancer Sequencing Kits detect low occurrence variants, as low as 5% in tumor samples, and work effectively with FFPE samples and low input DNA, as low as 25 ng of input DNA.
Low
Sequencing Costs
Offer significant savings on next generation sequencing with superior enrichment efficiency, and a target size at least 15 times smaller than whole exome sequencing, making it cost effective to be incorporated in cancer research that adopts the molecular disease approach.
Cancer Sequencing
Molecular Profiling
The Promises of Molecular Subtypes
Cancer is a complex genetic disease. There are over 100 different types of cancer and most cancers involve multiple genetic variants. In addition, patients with the same types of cancer often exhibit diverse genetic variation profiles, progression rates, and responses to standard treatments, presenting significant challenges for clinicians to provide accurate prognoses.
Recent research incorporating the Molecular Subtypes model has resulted in discoveries of genetic variants in cancer pathways, which in turn led to more targeted treatment therapies. As medical researchers continue to adopt the molecular disease model in cancer analysis, it will lead to a better understanding of the molecular mechanisms that drive the disease and open up opportunities for more accurate diagnosis and targeted therapies.
Challenges with a Fast-Evolving Cancer Genetic Landscape
As the number of cancer pathway discoveries and treatment therapies continue to grow, medical researchers are faced with the challenges of effectively incorporating the latest discoveries into their research for comprehensive analysis of the vast number of cancer pathways.
Molecular diagnostics with small cancer panels require multiple tests, which could quickly exhaust the small amounts of tumor cells in the samples. Whole exome and whole genome sequencing generate huge amount of data unrelated to cancer and are often too costly for routine cancer analysis.
RightOn: The Comprehensive Cancer Profiling Solution
RightOn Cancer Sequencing Kits enable comprehensive cancer profiling with one single test. A 1,000 cancer genes panel, coupled with superior on-target efficiency, provide a convenient, accurate, and cost-effective solution for profiling ALL cancer types.
Designed with an advanced enrichment technology, RightOn Cancer Sequencing Kits achieve 100x coverage for > 98% of targeted bases and can detect variants as low as 5% in tumor samples. This deep coverage and high sensitivity provide a convenient, accurate and cost-effective cancer enrichment solution best suited in a fast-evolving molecular landscape.
RightOn Cancer Sequencing
How Does It Work?
Cancer genotyping in the clinical setting demands high coverage to achieve the analytical sensitivity for detecting low frequency variants in heterogeneous specimens. At the present time, this is only achievable in practice with sub-exome targeted gene panels. Elim has developed a broad, 1000 cancer gene panel for next generation sequencing based on enrichment by liquid phase hybridization and targeting all coding exons and intron-exon junctions of the selected genes. The design of the panel contains 3 tiers of genes related to cancer:
1
2
3
The assay has been developed comprehensively as a library construction and capture kit (RightOn Cancer Sequencing Kit) which will accommodate small quantities of formalin-fixed paraffin-embedded clinical DNA samples. Performance of the assay shows minimum 100X coverage for more than 98% of the target bases at a sequencing throughput of 5 gigabases per sample. Such high on target coverage allows robust detection for single nucleotide variants, insertions/deletions, and copy number changes. The kit has been validated with a variety of clinical specimens previously genotyped by traditional single base genotyping, PCR sizing, and fluorescence in situ hybridization techniques. This is one of the largest cancer gene panel developed so far with a focus on high coverage for sensitive detection of low frequency variants. In contrast to current commercially available exome capture kits which show incomplete coverage for many genes, the RightOn Cancer Sequencing Kit offers a nearly complete and high coverage cancer sequencing option for clinical application and discovery.
RightOn Cancer Sequencing
Specifications
RightOn Cancer Sequencing Kits incorporate Elim’s expertise in oligo synthesis and proprietary technology in solution-based DNA target enrichment. The kits, designed with superior on-target efficiency, provide unparalleled accuracy and reliability for sequencing >1,000 cancer genes with a single test.
RightOn Cancer Sequencing Kits provide reagents for library construction as well as target enrichment.
Library Construction
- High efficiency library preparation specifically designed for low input DNA samples, as low as 25 ng input DNA.
- Perfect for library construction of precious samples in limited quantity, such as FFPE.
- Includes 12 indices for multiplexing.
- Libraries compatible with the latest Illumina and Ion Torrent sequencing platforms.
Target Enrichment
- Complete cancer panel that targets 3.6 Mb of exon regions and intron-exon junctions for 1,000 cancer related genes.
- Special bait design provides all targeted regions with the greatest uniform coverage.
- Achieve 100x coverage on >98% of the targeted bases with relatively low sequencing data.
- Optimized design and formulation greatly reduce duplicate generation, an issue found in other small panel sequencing kits.
| Number of Genes | 1,000 cancer genes |
| Target Bases | v1: 3.6 Mb, all coding exons and intron-exon junctions |
| Design Database | Extensive databases including UCSD, Sanger & NCBI |
| Kit Sizes (reactions) | 6, 24, 96 |
| 100x Minimum Coverage | >98% |
| Amount of Data Required | 5 to 6 Gb |
| Kit Type | Reagents for library preps & oligonucleotide probes |
| Sequence platform compatibility | Major platforms, including the latest Illumina and Ion Torrrent |
| Barcoding compatibility | Illumina and other major indices |
| Technical applications | Life science research |
| Pricing | Please contact Elim for price quotes. |
RightOn Cancer Sequencing
Superior Performance
Designed with advanced library prep and enrichment technologies, RightOn Cancer Sequencing Kits feature exceptional coverage and specificity, as well as high sensitivity for superior performances.
Exceptional Coverage
Figure 1 shows the percent of target bases covered as sequencing increases at four sequencing depths. With 5 – 6 GB sequencing, RightOn can achieve 100x minimum coverage for >98% of targeted bases.
Exceptional Coverage
Figure 1 shows the percent of target bases covered as sequencing increases at four sequencing depths. With 5 – 6 GB sequencing, RightOn can achieve 100x minimum coverage for >98% of targeted bases.
High Specificity
Figure 2 illustrates the exceptional high specificity exhibited by RightOn Cancer Sequencing, where only the targeted regions are enriched.
High Specificity
Figure 2 illustrates the exceptional high specificity exhibited by RightOn Cancer Sequencing, where only the targeted regions are enriched.
High Sensitivity
| Coverage for low Input DNA Samples | ||||||||
| Sample Name | Blood DNA 1 | Blood DNA 2 | FFPE 1 | FFPE 2 | ||||
| DNA Input Quantity | 50 ng | 50 ng | 50 ng | 50 ng | ||||
| Sequencing Data | 3.1 G | 9.1 G | 3.0 G | 5.9 G | 3.0 G | 7.3 G | 3.3 G | 7.0 G |
| 1x Min. Coverage | 99.64% | 99.97% | 99.64% | 99.96% | 99.77% | 99.95% | 99.75% | 99.95% |
| 50x Min. Coverage | 98.33% | 99.62% | 98.33% | 99.45% | 98.51% | 99.57% | 98.77% | 99.54% |
| 100x Min. Coverage | 96.14% | 99.09% | 96.38% | 98.49% | 95.44% | 98.93% | 96.92% | 98.89% |
RightOn Cancer Sequencing
Enrichment Technology
RightOn Cancer Research Collaboration
We have excellent results in the testing of RightOn Cancer Sequencing Kits, conducted in collaboration with the Pathology Department of Massachusetts General Hospital (MGH). If you are interested in validating the MGH results or using RightOn Cancer Sequencing Kits to advance your cancer research, we would like to hear from you.
For research collaborators, we offer special pricing on RightOn Cancer Sequencing Kits as well as research co-authoring publication opportunities. Please contact Elim Bio for more details.
Order Information
| RightOn Products | Size | Catalog # |
| RightOn 1000 Cancer Genes NGS Kit, Illumina, v1* | 6 samples | 06 201 0001 01 |
| RightOn 1000 Cancer Genes NGS Kit, Illumina, v1* | 24 samples | 06 201 0001 02 |
| RightOn 1000 Cancer Genes NGS Kit, Illumina, v1* | 96 samples | 06 201 0001 03 |
| RightOn 1000 Cancer Genes NGS Kit, Illumina, v1, Low Input ** | 6 samples | 06 201 0001 01 |
| RightOn 1000 Cancer Genes NGS Kit, Illumina, v1, Low Input ** | 24 samples | 06 201 0002 02 |
| RightOn 1000 Cancer Genes NGS Kit, Illumina, v1, Low Input ** | 96 samples | 06 201 0002 03 |
* For Research Use Only, Standard DNA Input 250ng
** For Research Use Only, Low DNA Input 100ng or less